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Abstract
Purpose The aim of this study is to investigate the factors that
influence implementation of Survivorship Care Plans (SCPs) in
the intervention arm of the ROGYCare trial by (1) assessing the
level of SCP receipt in the ROGY Care trial and (2) identifying
patient- and provider-level factors that influence SCP receipt.
Methods Between 2011 and 2015, a pragmatic cluster
randomized-controlled-trial was conducted on the effects of
automatically generated SCPs. Endometrial (N = 117) and
ovarian (N = 61) cancer patients were allocated to ‘SCP care’,
as provided by their SCP care providers (N = 10).
Associations between SCP receipt (self-reported SCP receipt
and actually generated SCPs), patient-factors (socio-demo-
graphic-, clinical-, and personality factors), and care provider
factors (profession and a-priori motivation regarding SCP pro-
vision) were tested in univariate analysis. The odds ratios of
factors influencing self-reported SCP receipt were estimated
with a multivariate regression model.
Results Of all patients in the SCP care arm (N = 178), SCPs
were generated by the care provider for 90 % of the patients
and 70 % of the patients reported that they had received an
SCP. Patients with older age, ovarian cancer, type D
(distressed) personality, and patients that completed the ques-
tionnaire a longer period of time after the SCP consult were
more likely to report no SCP receipt.
Conclusions SCP receipt was influenced by patient- but not
care-provider factors.
Implications for cancer survivors Certain patient groups were
less likely to report SCP receipt. Whether all patients are in
need of an SCP, requires further investigation. If they do, more
efforts need to be made towards the implementation of SCPs.
Keywords Survivorship care plan . Implementation .
Information provision . Gynecologic cancer
Introduction
In 2006, the American Institute of Medicine (IOM) and the
Dutch Health Council advocated Survivorship care plans
(SCPs) as a standard of care for all cancer patients [1, 2]. An
SCP is a formal document that is handed to the patient and
includes a record of all care received, important disease char-
acteristics of the patient, short- and long-term effects of the
treatments received and information for supportive care ser-
vices [1]. SCPs aim to promote cancer survivors’ follow-up
care and outcomes [1]. However, since the IOM’s recommen-
dations, implementation and dissemination of SCPs in clinical
practice have been low and inconsistent [3–6].
Our recently published study of the pragmatic cluster-
randomized ROGY Care trial [7] was accompanied by an
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editorial declaring the need for more attention to implementa-
tion of SCPs [8]. The ROGY Care study contributes to the
small number of clinical trials that have evaluated the effects
of SCPs on patient reported outcomes [9–11]. Published SCP
trials could not draw definite conclusions on SCP effective-
ness and highlighted the complexity of SCP implementation
[7, 9–11]. It is therefore recognized that, alongside investiga-
tions of the effectiveness of SCPs, we need to understand how
SCPs were implemented and compare implementation strate-
gies between SCP trials [8, 12]. The pragmatic nature of the
ROGY Care trial provides the unique opportunity to evaluate
implementation of SCPs in clinical practice.
Evaluations of intervention implementation often in-
clude a measure of fidelity—that is, the degree to which
an intervention was delivered as intended [13]. The im-
plementation fidelity of SCPs (i.e., the content of the SCP,
the coverage of patients that receive SCPs and the fre-
quency of SCP receipt) is expected to have an impact on
survivors’ outcomes [8]. Subsequently, poor implementa-
tion fidelity of SCP care in clinical trials would diminish
the observed effects of SCPs, leading to an underestima-
tion of true SCP effectiveness [13].
Little is known about the factors that influence implemen-
tation of SCPs. Current evidence is predominantly based on
qualitative studies that focus on system- and organizational
level factors that influence SCP implementation, including
organizational resources, adequate (electronic) systems, tem-
plates, and training for SCP use [3, 14–19]. A few observa-
tional studies have revealed that patients with lower age, non-
white race, higher income, higher educational level, better
than fair health status, and patients that participated in a trial,
more often reported receipt of an SCP [4, 19–21]. However,
generalizability of these observational studies is limited due to
patient selection bias. Furthermore, in these studies, only self-
reported receipt of SCPs by patients was available [4, 19–21].
To our knowledge, no SCP effectiveness randomized con-
trolled trials have yet examined the factors that influence im-
plementation of SCPs.
The ROGY Care trial provides longitudinal quantita-
tive data on a wide range of patient-level and provider-
level factors, along with both objective and self-reported
implementation outcomes of SCPs in routine Dutch clin-
ical practice. Patient-level factors include demographic,
clinical, and personality characteristics, and provider-
level factors include demographic characteristics, profes-
s i o n , a n d a - p r i o r i o p i n i on s r e g a r d i n g SCPs .
Understanding factors that promote or inhibit successful
implementation of SCPs in the ROGY Care trial can sup-
port future implementation of SCPs [8, 12].
The aim of the current study is to investigate factors that
influence implementation of SCPs in the ROGY care trial by
(1) assessing the level of SCP receipt and (2) identifying
patient- and provider-level factors that influence SCP receipt.
Methods
Design
Between April 2011 and October 2015, the pragmatic cluster-
randomized ROGY Care trial was conducted to evaluate the
impact of an automatically generated SCP on gynecological
cancer patient and health care provider reported outcomes. In
the South of the Netherlands, 12 hospitals were randomized to
either ‘usual care’ or ‘SCP care’. After initial diagnosis, all
endometrial and ovarian cancer patients were invited to par-
ticipate in the study. Patients were invited with a letter, in-
formed consent form, and questionnaire, sent to the patient
by their own gynecologist [22, 23]. Follow-up questionnaires
were sent directly to the patient at 6, 12, 18, and 24 months
after diagnosis. Patients, but not care providers, were blinded
to trial assignment. The ROGY Care trial was centrally ap-
proved by a Medical Research Ethics Committee, as well as
by each participating center [22]. The trial design has been
described in detail elsewhere [22]. The present study describes
the results of implementation fidelity in the intervention arm.
Patients and care providers
Participants include 117 newly diagnosed endometrial and 61
ovarian cancer patients that were in the intervention arm of the
ROGY Care trial and completed the first questionnaire, and
their ten SCP care providers (i.e., gynecologists, gynecologic
oncologists, and oncology nurses) in the six hospitals of the
intervention arm. A follow-up questionnaire was sent to the
patients 12 months after diagnosis. Follow-up questionnaires
were returned by 68 % (N = 79) of the endometrial and 57 %
(N = 35) of the ovarian cancer patients. Patient exclusion
criteria (i.e., undergoing palliative care or unable to complete a
Dutch questionnaire) [22] were minimal to maximize generaliz-
ability [24]. All care providers of the intervention arm (N = 10)
completed a questionnaire before the start of the trial [25].
Implementation of SCP care
In the hospitals that were allocated to ‘SCP care’, all care
providers attended an instruction evening. The care providers
were instructed to provide an SCP to patients after diagnosis
and to provide an updated SCP during follow-up visits if ap-
plicable (i.e., when there were changes in the cancer, treat-
ment, or oncology provider). In addition, care providers were
instructed to send a copy of the SCP to the patient’s primary
care physician [26]. Practical guidelines were given on the
components of the SCP that should minimally be discussed
with each patient during the SCP consult (i.e., diagnosis, prog-
nosis, treatment(s), and most important, side-effects) and how
often the SCP should be discussed (shortly after diagnosis and
during follow-up visits after 6, 12, 18, and 24 months). Care
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providers in the SCP care armwere instructed to provide the first
SCP at the consultation where the results of histopathology and
(adjuvant) treatment planwere discussed,mostly 7–14 days after
the operation or biopsy. Because of the pragmatic approach, care
providers in the SCP care hospitals were free to choose whether
the gynecologist/gynecologic oncologist, and/or oncology nurse
provided the SCP, fitting their clinical practice [22]. No other
care providers (i.e., medical oncologists or radiotherapists) were
involved in the trial because they do not use the registration
system through which SCPs were generated.
SCPs could be automatically generated through the web-
based ‘Registrationsystem Oncological GYnecology’
(ROGY), which is used by all participating oncology providers
in both arms since 2006. For each patient, a detailed registration
is made in a uniform way, including tumor stage and grade,
treatment, comorbidity, complications, follow-up, and informa-
tion about the involved specialists (e.g., gynecologist/
gynecologic oncologist, medical oncologist, and radiothera-
pist). For the ROGY Care trial, an application was built in
ROGY that enables automatic generation of an SCP combining
patient and disease data from ROGY. Care providers could
generate an SCP by pressing a button in ROGY. This button
was only visible for the care providers in the intervention arm.
Survivorship care plan
The SCP was based on the Dutch translation of IOM’s SCP
template [27], adjusted to the local situation [28] by a group of
gynecologists/gynecologic oncologists, oncology nurses, a radio-
therapist, medical oncologist, primary care physician, and pa-
tients [22]. Texts of the SCP were based on pilot-tested patient
education material from the Dutch Cancer Society. In addition,
the SCP was pilot-tested on patients with a low/intermediate
educational level to ensure that the SCP was understandable.
The SCP consisted of a tailored treatment summary includ-
ing information on diagnostic tests, type of cancer, stage,
grade, treatment(s) (type, date, and specialist), and contact
details of the hospital and specialists. The treatment summary
contained explanatory notes of the clinical information pro-
vided and visual representations of affected organs and cancer
stage. In addition, the SCP contained a tailored follow-up care
plan, including detailed information on the most common
short- and long-term effects of the treatments received, effects
on social and sexual life, possible signs of recurrence and
secondary tumors, and information on rehabilitation, psycho-
social support, and supportive care services [22].
Measures
SCP receipt
Receipt of SCPs was assessed by the number of patients for
whom SCPs were generated, the number of patients that
reported having received an SCP, the number of patients for
whom follow-up SCP(s) were generated, and the number of
patients that reported having received a follow-up SCP. The
number of patients of whom (first and follow-up) SCPs were
generated was obtained from ROGY. ROGY recorded wheth-
er the SCP was generated for the patient by a care provider.
Whether the patients actually received the SCP was based on
self-report, by asking ‘Did you receive a survivorship care
plan?’. No further explanation about the SCP was given in
the questionnaire to avoid feelings of disadvantage in the con-
trol arm. Follow-up SCP receipt was assessed by follow-up
questionnaires (‘How often did you receive a survivorship
care plan?’), on 6 and 12 months after diagnosis. Patients that
reported (first or follow-up) SCP receipt while no SCP was
generated in ROGY were allocated to ‘reported no (first or
follow-up) SCP receipt’, because it was not possible to receive
an SCP when not generated.
Patient factors
Age, socioeconomic status (SES) and clinical data, such as
cancer type, cancer stage, and date of diagnosis, were obtained
from the Netherlands Cancer Registry (NCR). The NCR rou-
tinely collects data on newly diagnosed cancer patients in all
hospitals in the Netherlands [29]. SES was based on postal
code of the residence area of the patient, combining aggregat-
ed individual fiscal data on the economic value of the home
and household incomes [30]. SES was categorized into low,
medium, or high.
Shortly after diagnosis, a first questionnaire was sent to
the patient to assess partner status, the number of comor-
bidities and Type D personality. Partner status was dichot-
omized (having a partner vs. not having a partner). The
number of comorbidities was assessed by the adapted self-
administered comorbidity questionnaire (SCQ) [31]. Type
D (distressed) personality is defined as the joint tendency
towards negative affectivity (e.g., worry, irritability, and
gloom) and social inhibition, and has previously been as-
sociated with lower perceived receipt of information in
cancer patients [32]. Type D personality was assessed by
the Type D scale (DS14) [33].
In a follow-up questionnaire 12 months after diagnosis,
health literacy was measured by one item of the 5-point
Chew’s scoring scale (‘How confident are you by filling out
medical forms?’) [34]. Low health literacy was defined as
being somewhat, a little or not at all confident filling out
medical forms, medium health literacy was defined as being
quite confident filling out medical forms, and high health lit-
eracy was defined as being very confident filling out medical
forms [34]. Furthermore, the time between SCP consult and
completion of questionnaire was calculated by the difference
in weeks between first treatment received (obtained from the
NCR) and the date of filling out the first questionnaire.
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Care provider factors
The primary care provider (i.e., gynecologist or gynecologic
oncologist) that was in charge of the SCP care of the patient,
was registered in ROGY. In three out of six hospitals in the
intervention arm, the provision and discussion of the SCP was
delegated to an oncology nurse. Age, sex, and motivation of
the care providers regarding SCP provision and opinion about
SCP benefit were measured by a questionnaire among all care
providers before the start of the trial [25]. Motivation regard-
ing SCP provision (‘How motivated are you to start using the
SCP?‘) and opinion about SCP benefit (‘To what extent do
you expect the SCP to affect the patient positively?’) were
measured on a 10-point scale (strongly disagree—strongly
agree).
Statistical analysis
Statistical analyses were conducted using Statistical
Analysis System (SAS) version 9.4. (SAS Institute,
Cary, NC, 1999). Means with standard deviations (SD)
were used to describe normally distributed continuous
variables, medians, and interquartile ranges (25th–75th)
to describe not normally distributed variables and fre-
quencies (N) with percentages (%) to describe categorical
variables. All patient- and care provider-level factors
influencing SCP receipt were assessed in univariate anal-
ysis, using independent samples t tests for normally dis-
tributed continuous variables, Mann—Whitney U Test for
not normally distributed continuous variables and Chi2-
tests for categorical variables. For categorical variables
with an expected count less than five, Fisher’s exact tests
were used. In the main analysis, the dependent variable
was SCP receipt as reported by the patient. In additional
analyses, dependent variables were generated SCPs, re-
ported receipt of follow-up SCPs and generated follow-
up SCPs. Independent variables were patient- or provider-
level factors. Independent variables with a significance
level greater than 0.05 were entered into a multivariable
logistic regression model using a forward selection meth-
od. For each selected independent variable, the odds of
SCP receipt as reported by the patient was estimated (SCP
received vs. no SCP received). A significance level of
0.05 was used.
Results
SCP receipt
Of all 178 patients in the intervention arm of the trial, an SCP
was generated for 90 % of the patients (N = 161). From the
patients for whom an SCP was generated, 78 % (N = 125)
reported receipt of an SCP (Fig. 1).
Patient and SCP care provider factors related to SCP
receipt
In univariate analysis, patients who reported first SCP receipt
were significantly younger (65 years versus 70 years,
p < 0.01) and less often had Type D personality (15 % vs.
31 %, p = 0.02) compared to patients that reported no first
SCP receipt (Table 1). In endometrial cancer patients, first
SCPs were more often received by patients with an advanced
FIGO stage (Table 1). No SCP care provider factors were
associated with first SCP receipt (Table 2). Multivariate anal-
ysis showed that older age, having ovarian cancer vs endome-
trial cancer, having Type D personality versus no type D per-
sonality and completion of the questionnaire a shorter period
of time after the SCP consult were all independently associat-
ed with a lower chance of report of first SCP receipt (Table 3).
Follow-up SCPs were reported as received by 21 %
(N = 27) of the patients (data not shown). Reported receipt
of follow-up SCPs was associated with a hospital (p < 0.01)
and having an oncology nurse as SCP provider compared to a
gynecologist/oncologic gynecologists (31 vs. 10 %, p < 0.01)
(not tabulated). No patient factors were associated with receipt
of follow-up SCPs.
Additional analyses showed that first SCPs were more of-
ten generated for endometrial compared to ovarian cancer
patients (95 vs. 82 %, p < 0.01). Follow-up SCPs were also
more often generated for endometrial compared to ovarian
cancer patients (24 vs. 11 %, p = 0.04) and more often for
ovarian cancer patients who had surgery only compared to
ovarian cancer patients who also had chemotherapy (40 vs.
9 %, p = 0.04) (not tabulated).
In addition, 36 patients (20 %) for whom a first SCP was
generated (Ntotal = 161) did not report receiving an SCP. These
patients were significantly older compared to patients who
reported first SCP receipt (71 [SD 8.0] vs. 65 [SD 10],
p < 0.01) (not tabulated).
Discussion
In this study of endometrial and ovarian cancer survivors in
the intervention arm of the ROGY Care trial, first SCPs were
generated for 90 % of the patients and reported as received by
70 % of the patients. Follow-up SCPs were reported as re-
ceived by 21% of the patients. Patient factors, including being
older, having ovarian cancer and having a Type D personality
were independently associated with a lower chance of per-
ceived receipt of first SCPs, while having an oncology nurse
as care provider was associated with higher perceived receipt
of follow-up SCPs.
J Cancer Surviv (2017) 11:64–73 67
To our knowledge, this is the first study that examines
patient and care provider factors associated with SCP receipt
in a trial. The self-reported SCP receipt in our trial is substan-
tially higher compared to the coverage ranging between 24
and 58 % in observational studies [35]. This is probably relat-
ed to the ease with which the SCP could be automatically
generated through ROGY by clicking a button. However,
due to the pragmatic nature of the trial, 100 % dissemination
of SCP receipt was not attained.
Interestingly, we found that a considerable group of pa-
tients reported no SCP receipt while an SCP was generated.
These patients were older on average compared to patients
who did report receiving an SCP. There are two possible ex-
planations for this finding: SCP receipt may have been
underreported by older patients due to a recall bias, or during
consultation care providers decided more often not to hand
over the SCP to older patients. In line with our findings, youn-
ger age has previously been associated with higher self-
Randomized hospitals (n=12) 
Hospitals allocated to SCP care (n=6) Hospitals allocated to usual care (n=6)
Patients receiving questionnaire  (n=245)
Endometrial cancer (n=154)
Ovarian cancer (n=91) 
Patients receiving questionnaire (n=299)
Endometrial cancer (n=142)
Ovarian cancer (n=157)  
Patients completing questionnaire (n=180)
Endometrial cancer (n=119)
Ovarian cancer (n=61) 
Patients completing questionnaire (n=216)
Endometrial cancer (n=102)
Ovarian cancer (n=114)  
SCP was generated for
patients (n=161)
Endometrial cancer (n=111)
Ovarian cancer (n=50)  
SCP was not generated
for patients (n=17)
Endometrial cancer (n=6)
Ovarian cancer (n=11)  
Patients included in analysis (n=178)
Endometrial cancer (n=117)
Ovarian cancer (n=61)  
Patients reported SCP.
receipt (n=125)
Endometrial cancer (n=85)
Ovarian cancer (n=40)  
Patients reported no SCP
receipt (n=53)
Endometrial cancer (n=32)
Ovarian cancer (n=21)  
SCP was generated but
patients did not report
SCP receipt (n=36)
Endometrial cancer (n=26)
Ovarian cancer (n=10)  
Not included in analysis because no SCP care condition
Not included in analysis (n=2)
Fig. 1 Flow diagram of patients included in analysis and (first) SCP receipt in the ROGY care trial
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reported SCP receipt in observational studies [20, 21]. This
has formerly been explained by a higher need for instructions
for follow-up care in younger cancer patients [20]. In addition,
recall bias may explain lower self-reported SCP receipt in
older patients.
Cancer type has also previously been associated with differ-
ences in SCP receipt. In two observational studies, patients with
more common types of cancer, including breast-, prostate-,
lung-, and colorectal- cancer reported SCP receipt more often
compared to patients with less common types of cancer such as
melanoma and gynecological cancers [20, 21]. It is possible that
this is related to the fact that SCP templates are less available for
less common types of cancer [3, 36]. SCP receipt in endometrial
and ovarian cancer patients specifically has not previously been
investigated. Brothers and coworkers’ SCP trial in gynecologi-
cal cancer patients did not examine how many SCPs were actu-
ally received in the intervention arm [9]. Our study showed that
SCPs were more often generated for, and more often reported as
Table 1 Patient factors of
reporting first SCP receipt SCP Received
(N = 125)
SCP Not received
(N = 53)
P
value
Age, mean (SD) 64.7 (10.2) 70.4 (8.6) <0.01
Cancer type, N (%)
Endometrial 85 (68) 32 (60) 0.33
Ovarian 40 (32) 21 (40)
Endometrial cancer
FIGO stage, N (%)
I 68 (80) 32 (100) 0.051
II 6 (7) 0 (0)
III 9 (11) 0 (0)
IV 2 (2) 0 (0)
Treatment type
Surgery only 53 (64) 16 (50) 0.07
Radiotherapy 25 (30) 16 (50)
Chemotherapy 5 (6) 0 (0)
Ovarian cancer
FIGO stage, N (%)
I 15 (38) 6 (28) 0.43
II 6 (15) 1 (5)
III 14 (35) 9 (43)
IV 5 (12) 5 (24)
Treatment type
Surgery only 10 (26) 5 (25) 0.96
Chemotherapy 29 (74) 15 (75)
SES, N (%)
Low 20 (18) 12 (25) 0.14
Medium 41 (36) 21 (45)
High 53 (47) 14 (30)
Partner
Yes 93 (76) 38 (73) 0.66
No 29 (24) 14 (27)
Health literacya, N(%)
Low 38 (45) 7 (28) 0.15
Medium 40 (47) 13 (52)
High 7 (8) 5 (20)
Type D personality, N (%)
Yes 18 (15) 15 (31) 0.02
No 105 (85) 34 (69)
Comorbidities, N (%)
0 17 (14) 4 (8) 0.09
1 32 (26) 21 (43)
>1 75 (60) 24 (49)
Weeks between SCP consult and questionnaire, median
(25th–75th)
10.7 (7.0–14.6) 11.2 (7.0–15.9) 0.43
a Low being somewhat, a little or not at all confident filling out medical forms; medium being quite confident
filling out medical forms; high being very confident filling out medical forms. Health literacy was unknown for
n = 68
P values are based on independent samples t tests for continuous variables and Chi2 -tests/ Fisher’s exact tests for
categorical variables
All percentages stated are column percentages
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received by, endometrial cancer patients compared to ovarian
cancer patients. Maybe, SCP care providers perceive more bar-
riers to providing information to cancer patients with worse
prognosis. This is in accordance with literature showing that
health care providers are often reluctant to provide information
on late effects in order to prevent disproportionate fear in the
patient [37]. Further, ovarian cancer patients less often received
follow-up SCPs when they had chemotherapy compared to sur-
gery only. This could be explained by the fact that during
chemotherapy, treatment of the patient is scheduled for follow-
up visits at the medical oncologist instead of the gynecologist/
oncologic gynecologist [25]. Medical oncologists were not in-
volved in our trial and therefore did not provide SCPs.
Besides younger age and cancer type, other studies found
that higher SES is associated with higher perceived SCP re-
ceipt [20, 21]. In addition, higher health literacy has been
associated with higher perceived information provision [38].
Although we did not find statistically significant differences,
Table 2 SCP provider factors of
reporting first SCP receipt SCP received (N = 125) SCP not received (N = 53) P value
Hospital, N (%)
1 27 (22) 10 (19) 0.98
2 14 (11) 6 (11)
3 23 (18) 10 (19)
4 36 (29) 17 (32)
5 10 (8) 4 (8)
6 15 (12) 6 (11)
SCP Care provider, N (%)
Gynecologist/ OG 63 (50) 27 (51) 1.00
Oncology nurse 62 (50) 26 (49)
Age SCP provider, mean(SD)
43.5 (5.0) 43.2 (5.2) 0.75
Gender SCP provider, N (%)
Male 9 (7) 4 (8) 1.00
Female 116 (93) 48 (92)
Motivation regarding SCP provision, mean (SD)
Range 0–10 8.1 (0.7) 8.0 (0.7) 0.94
Opinion about SCP benefit, mean (SD)
Range 0–10 7.4 (1.1) 7.4 (1.1) 0.90
P values are based on independent samples t tests for continuous variables and Chi2 -tests/ Fisher’s exact tests for
categorical variables
Table 3 Odds ratio’s (OR) of
first SCP receipt versus no first
SCP receipt
SCP received versus not received (N = 146)
OR 95 % CI P
value
Age, per 10 years 0.35 0.20–0.57 <0.01
Cancer type,
Endometrial 1.00 (ref)
Ovarian 0.31 0.12–0.83 0.02
Type D personality,
Yes 0.28 0.11–0.73 <0.01
No 1.00 (ref)
Comorbidities
0 1.00 (ref) 0.07–1.65
1 0.37 0.21–4.82 0.22
>1 1.12 0.89
Time between SCP consult and questionnaire, per week 0.95 0.90–1.00 0.04
Candidate variables for multivariate regression were all patient factors (age, cancer type, FIGO stage, treatment
type, socio-economic status, health literacy, Type D personality, number of comorbidities and number of weeks
between SCP consult and questionnaire) and care provider factors (hospital, SCP Care provider, age, gender,
motivation regarding SCP provision and opinion about SCP benefit). Candidate variables with a significance level
higher than 0.05 were entered into a multivariate regression model using a forward selection method. Selected
variables were entered into a separate multivariate regressionmodel in order to include all patients in themodel for
whom data was available on selected variables.
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our data suggest positive trends between SES and perceived
SCP receipt, and health literacy and perceived SCP receipt.
To date, no patient personality factors have been studied
in relation to SCP receipt. Our study shows that patients
with a Type D personality (a combination of negative af-
fect and social inhibition), were more likely to report no
SCP receipt. Patients with this personality type have the
tendency to experience increased negative emotions and
tend not to share these emotions because of fear of rejec-
tion or disapproval [33]. In this study, 19 % of the patients
had a Type D personality, which is comparable to 21 % in
the general population [33]. Other studies have shown that
cancer patients with a Type D personality are less likely to
report receipt of both oral and written information [32].
SCP receipt in patients with a Type D personality may
have been underreported. This may be due to negative
emotions they experience towards medical information
[32], or because SCP care providers may be more reluctant
to provide SCPs for patients that are more inhibited and
less likely to ask for information. Future research should
explore whether information needs are lower among pa-
tients with a Type D personality and consequently whether
lower provision of SCPs for patients with a Type D per-
sonality is desired.
A minority of the patients in our study received a
follow-up SCP. We found that follow-up SCP receipt, but
not first SCP receipt, was higher in hospitals where SCP
care was delegated to an oncology nurse. This was mainly
due to the presence of one oncology nurse that provided
SCP care for a large number of the patients in our analysis.
Therefore, the generalizability of this finding is question-
able. Moreover, we could not adjust for the patients’ need
of an updated SCP (i.e., when there were changes in the
cancer, treatment, or care provider), which could have bi-
ased our results. However, previous studies also suggest
that oncology nurses promote successful implementation
of SCPs [18, 39]. Consistently, prior results from the
ROGY Care trial showed that oncology providers in our
study (i.e., gynecologists, gynecologic oncologists and on-
cology nurses) prefer oncology nurses to provide SCPs in
their practice [25]. Therefore, for improved implementation
of follow-up SCPs, delegation of SCP care to an oncology
nurse is recommended. However, oncology nurses did not
provide first SCPs more often compared to gynecologists/
oncologic gynecologists in our study.
Another suggestion to improve implementation of
follow-up SCPs may be that the follow-up SCPs’ content
is tailored to the information needs of the patient during
follow-up. In our trial, follow-up SCPs only differed from
first SCPs when there were substantial differences in the
treatment or care provider. If other information is provided
in a follow-up SCP than the first SCP, care providers
would probably be more prone to provide follow-up
SCPs. Further, it would probably be helpful for the care
provider if a reminder is sent when a follow-up SCP needs
to be delivered.
A strength of the current study is the trial design, in
which large numbers of patient- and SCP care provider fac-
tors were measured along with longitudinal objective and
subjective measures of SCP receipt. In addition to self-
reported receipt of SCPs that has been examined in previous
literature, we were able to examine whether an SCP was
generated or not. This revealed new insights into, for in-
stance, a possible recall bias of reported SCP receipt related
to older age, and more certainty about factors influencing
actual SCP receipt including cancer type and Type D
personality.
In order to maximize the generalizability of our trial
results, the ROGY Care trial is characterized by a pragmat-
ic approach; exclusion criteria for patient inclusion were
limited and oncology providers were free to choose how
the SCP provision was integrated in clinical practice.
Despite the pragmatic nature of the trial, however, adher-
ence to SCP provision by the care providers was probably
higher than we would expect in clinical practice outside a
trial setting [3, 36]. For instance, SCP care providers in our
trial frequently received reminders for patient inclusion and
providing an SCP if not done so yet. This is reflected by a
relatively long period between SCP provision and comple-
tion of the questionnaire by the patient. Our findings may
therefore not be fully generalizable to everyday routine
clinical practice.
Limitations of our study include the uncertainty of our
measure of SCP receipt; although we were able to objec-
tively examine whether an SCP was generated through
ROGY, we are not sure whether the SCP was handed over
to the patient. Therefore, we have to rely on self-report of
the patient. However, our results suggest that the self-
reported assessment of SCP receipt may have been affected
by recall bias in older patients. Besides that, independent
from age, patients who completed the questionnaire a lon-
ger period of time after the SCP consult were more likely
to report no SCP receipt. A delay in completion of the ques-
tionnaire was either caused by a longer time needed for the
gynecologist to include a patient in the study and sending the
questionnaire, or by the patient taking a longer time before
filling out the questionnaire after receiving the questionnaire.
Either way, this may indicate a recall bias of self-reported SCP
receipt. Future studies should therefore aim to include a more
reliable measure of SCP receipt in the study, for instance by
sending a questionnaire shortly after SCP receipt in order to
prevent recall bias. Alternatively, SCP receipt could be record-
ed by the care provider, but this may result in over-report of
SCP receipt due to a social desirability bias.
The level of implementation fidelity of SCPs in the
ROGY Care trial is expected to have an influence on the
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observed effectiveness of SCPs. When no 100 % coverage
of SCP receipt in the intervention arm is attained, a com-
parison between the intervention and control arm (intention
to treat analysis) may result in an underestimation of SCP
effectiveness on patient reported outcomes. Therefore, a
per protocol analysis could provide a more accurate esti-
mation, by only comparing patients who reported SCP re-
ceipt to all patients in the usual care arm [7]. The current
study shows, however, that SCP receipt may have been
underreported due to recall bias. Subsequently, only pa-
tients who accurately remembered SCP receipt (i.e., be-
cause of younger age or more extensive discussion of
SCP by the care provider) were included, which may result
in an overestimation of SCP effectiveness. Therefore, both
types of analysis require careful interpretation. It remains
debatable whether a per protocol analysis based on actually
generated SCPs instead of self-reported SCP receipt would
better reflect SCPs effectiveness in the ROGY Care trial.
Our findings can support future implementation of SCPs in
clinical practice if widespread implementation is decided upon,
or future clinical trial research. Disparities in SCP care could be
reduced by paying particular attention to older patients and pa-
tients with ovarian cancer, who appear to less often receive SCPs.
In addition, care providers providing SCPs should pay particular
attention to patients with a TypeD personality, as they experience
more negative emotions towardsmedical information and are not
likely to ask for information themselves. However, the question
arises whether all patients are in need of information as provided
in an SCP. For instance, whether patients with a distressed per-
sonality benefit from SCP receipt instead of unnecessarily accu-
mulating psychosocial distress requires further investigation [7].
Possibly, more personalized SCPs (i.e., modules fitting individ-
ual patients’ information needs) could promote information pro-
vision for cancer survivors in clinical practice.
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